Publications
320 publications
Sort by: Date / Relevance
GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia
Zorginstituut Nederland has completed its assessment whether glucagon nasal powder (Baqsimi®) for the treatment of severe ...
GVS assessment of ozanimod (Zeposia®) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS)
Zorginstituut Nederland has completed its assessment whether ozanimod (Zeposia®) for the treatment of adult patients with ...
GVS assessment of amisulpride (Aktiprol®) for the treatment of schizophrenia
Zorginstituut Nederland has completed its assessment whether amisulpride (Aktiprol®) can be included in the GVS. ...
Package advice esketamine nasal spray (Spravato®) for the treatment of adults with treatment-resistant major depressive disorder
Zorginstituut Nederland has completed its assessment whether esketamine nasal spray (Spravato®) can be included in the insured ...
Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage
Zorginstituut Nederland has completed its assessment whether trastuzumab-emtansine (Kadcyla®) can be included in the insured ...
Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients
Zorginstituut Nederland has completed its assessment whether Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) can be ...
Indacaterol acetate/mometasone furoate (Atectura® Breezhaler®) for the maintenance treatment for asthma in adults and adolescents of 12 years and older
Zorginstituut Nederland has completed its assessment whether indacaterol acetate/mometasone furoate (Atectura® Breezhaler®) can ...
Osimertinib (Tagrisso®) for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) with an epidermal growth factor receptor (EGFR) mutation (reassessment)
The Minister of Medical Care has requested Zorginstituut Nederland to reassess whether osimertinib (Tagrisso®) for the treatment ...
Avelumab (Bavencio®) in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinoma
Zorginstituut Nederland has completed its assessment whether avelumab (Bavencio®) in combination with axitinib can be included in ...
GVS assessment of ivacaftor/tezacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) for the treatment of cystic fibrosis
Zorginstituut Nederland completed its assessment whether an extension is possible of the conditions of List 2 of the GVS ...